View clinical trials related to Hyponatremia.
Filter by:ICU patients with severe hyponatremia and a high risk of rapid SNa overcorrection.
Hyponatremia in COVID-19 patients with adrenal insufficiency
resolution of hyponatremia, defined as an increase in serum sodium of more than 5 mEq/L with a final value > 130 mEq/L, maintained for at least 48 consecutive hours during the 10-day treatment period
Cicletanine, which has been approved and launched for hypertension in France and Germany, has promise beyond hypertension in critically-unmet needs such as diabetes. It is evident from in vitro, animal and human studies that cicletanine's optimal dose in diabetes and other challenging, critically-unmet needs is likely to be higher than that for hypertension. Cicletanine's maximum tolerated dosage is not known, but the drug's dose-limiting effects are documented to be potassium loss and sodium loss from thiazide-type activity (one of the therapeutic mechanisms the drug is known to have); such thiazide-type losses are known to be reversed safely by magnesium. This trial explores the ability of magnesium to enhance cicletanine safety at higher doses in a trial involving patients with hypertension complicated by diabetes.
Prospoctive cohort of high-dose cyclophosphamide exposed patients. With active estandardize screening of hyponatremia development in the follow up period.
The purpose of the study is to investigate the efficacy and safety for the management of hyponatremia and ascites in patients with liver cirrhosis.
The aim of this study is to identify factors associated with hyponatremia among patients hospitalized in the internal medicine ward. Consequtive patients hospitalized because of hyponatremia will be recruited. Follow up will include clinical factors such as background diseases, complete drug history, blood tests including Biochemistry tests (Sodium, renal function), endocrinological evaluation, thyroid function tests, cortisol,urinary sodium on addmition. One month following discharge follow up Sodium level will be taken.
Hypothesis: the hyponatremia of multiple myeloma (m.m.)is true and not pseudohyponatremia by using the stewart approach to acid - base interpretation, would like to show that the positive charged m- proteins produced in m.m.result in true hyponatremia.